Søren Gersting
CEO
iniuva
Iniua develops AI-driven orphan drugs that target protein misfolding, a common mechanism in over 7,000 rare genetic diseases affecting children. By restoring the structure of these proteins, the company aims to provide effective treatments for conditions that currently lack therapeutic options.
- Artificial Intelligence
- Biotechnology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Over 7,000 rare genetic diseases, many affecting children, lack effective treatments. A significant portion of these diseases share a common underlying mechanism: protein misfolding, which disrupts protein function.
Solution
Iniua is developing AI-driven therapeutics focused on correcting protein misfolding in rare genetic diseases. The company's approach aims to restore the correct structure of misfolded proteins, thereby rescuing their function and providing potential treatments for conditions with limited or no existing therapeutic options. Iniua leverages artificial intelligence to identify and develop novel orphan drugs that address the root cause of these diseases at the molecular level.
Target Audience
The primary target audience includes children and families affected by rare genetic diseases, as well as pharmaceutical companies and research institutions focused on orphan drug development.
Features
- AI-driven drug discovery platform targeting protein misfolding
- Focus on rare genetic diseases with unmet medical needs
- Development of therapeutics to restore protein structure and function